Small cell lung cancer(SCLC) is a type of neuroendcorine cancer with high growth fraction, early metastatic spread and poor prognosis, accounting for approximately 15％ of all newly diagnosed lung cancer cases.Patients with SCLC are generally treated with platinum-based chemotherapy in combination with radiotherapy.Despite good responses to chemotherapy in the early stage of treatment, patients develop drug resistance and recurrence soon.There has been limited success with the targeted approaches in clinical trials completed in the past several years.Novel targeted and more effective treatment strategies for SCLC are in urgent need With increasing translational research and a better understanding of the molecular basis of small cell lung cancer, a number of new targeted drugs such as kinase inhibitors, angiogenesis inhibitors, apoptosis inducers, proteasome inhibitors, epigenetic regulators, immune checkpoint inhibitors have been developed and investigated in various preclinical studies.Some of them have entered clinical trials.At the same time, a number of novel treatment strategies such as immunotherapy and combination treatment receive attention.This review summarizes potentially molecular targeted therapies that have been developed and employed recently, and ongoing and future clinical trials in attempt to improve patient outcomes in SCLC, and meanwhile to invite future potential SCLC new treatment strategies.

现阶段传统的放化疗给胃癌带来了一定的生存获益，但胃癌总体生存率仍不理想。迫切需要继续挖掘新的治疗靶标 和诊断治疗方案。密封蛋白（claudin）是细胞连接复合体中紧密连接的重要组成成分，其异常表达导致的紧密连接功能失常会促 进肿瘤的增殖和转移。Claudin家族蛋白如claudin1、 4、 7、 18.2等的突变和表达水平异常影响胃癌细胞的增殖、侵袭、转移和凋亡 等，具有作为胃癌诊断、治疗和预后的生物标志物的巨大潜力。以靶向claudin18.2的药物IMAB362为代表，目前已开发出多种 针对claudin蛋白的靶向药物，相关的临床试验已在胃癌、胰腺癌、生殖细胞瘤以及卵巢癌等恶性肿瘤患者中开展，针对claudin蛋 白的研究可能有助于探寻胃癌的早期诊断和精准治疗的新策略。